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Tularemia in the United States is caused by 2 sub-
species of Francisella tularensis, subspecies tularensis
(type A) and subspecies holarctica (type B). We compared
clinical and demographic features of human tularemia
cases from 1964 to 2004 from 39 states in which an isolate
was recovered and subtyped. Our data indicate that type A
and type B infections differ with respect to affected popula-
tions, anatomic site of isolation, and geographic distribu-
tion. Molecular subtyping with pulsed-field gel
electrophoresis further defined 2 subpopulations of type A
(type A-east and type A-west) that differ with respect to
geographic distribution, disease outcome, and transmis-
sion. Our data suggest that type A-west infections are less
severe than either type B or type A-east infections. Through
a combined epidemiologic and molecular approach to
human cases of tularemia, we provide new insights into the
disease for future investigation.
T
ularemia is a zoonotic disease caused by the gram-neg-
ative bacterium Francisella tularensis (1).
Transmission occurs through arthropod bites (especially
ticks and deerflies), ingestion of contaminated food or
water, inhalation of contaminated aerosols, and handling
of infected animal tissues. Human illness usually takes 1 of
several clinical forms. The most common is ulceroglandu-
lar tularemia; more serious forms include pneumonic,
typhoidal, and meningitic tularemia.
Nearly all human cases of tularemia in the United
States are caused by F. tularensis subspecies  tularensis
(type A) or F. tularensis subspecies holarctica, (type B)
(2). Type Aand B isolates can be differentiated on the basis
of glycerol fermentation, virulence in animal models, and
by polymerase chain reaction (3–5). Recently, molecular
assays have been developed to further discriminate within
subspecies by using pulsed-field gel electrophoresis
(PFGE), multiple-locus variable–number tandem repeat
analysis (MLVA), whole-genome microarrays, and single
nucleotide variations (6–9). In nature, the 2 subspecies are
thought to be maintained in distinct but incompletely
defined cycles (10–12).
Although both subspecies of F. tularensis cause human
illness (10), the clinical and epidemiologic features of type
Aand type B infections have not been systematically com-
pared for a substantial number of cases. Furthermore, the
implications of other subgroupings, as defined by molecu-
lar techniques, are largely unknown. We identified to sub-
species level all human F. tularensis isolates that were
submitted to the Centers for Disease Control and
Prevention (CDC) for a 40-year period and further sub-
typed a portion by PFGE. Our findings demonstrate dis-
tinct subpopulations of F. tularensis that differ in their
clinical manifestations, geographic location, and likely
modes of transmission.
Methods
We analyzed all available F. tularensis isolates from
humans (n = 316) recovered by or submitted to CDC by
state and local health departments from 1964 through
2004. All work with F. tularensis cultures was performed
in a biosafety level 3 (BSL-3) laboratory using BSL-3
safety precautions. Isolates were confirmed as F. tularensis
by characteristic growth on agar and direct fluorescence
antibody staining. Type A and type B isolates were differ-
entiated by biochemical subtyping (glycerol fermentation)
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Demographic and clinical data on source patients were
extracted from submission forms that accompanied the
isolates. Extracted information included patient age and
sex, date of disease onset, form of clinical disease, anatom-
ic source of isolate, underlying illness, outcome, county
where infected, and likely mode of transmission. Isolates
received after 1990 (n = 155) were matched with patients
reported through the National Electronic Tele-
communication Surveillance System to extract county of
exposure. Information was verified by contacting the
reporting state health department.
PFGE subtyping was performed on a subset of isolates
with a modified version of the PulseNet 1-day standard-
ized protocol for subtyping foodborne pathogens (14,15).
A total of 41 type A and 22 type B isolates were used.
DNA-embedded agarose plugs were prepared and lysed
under BSL-3 conditions. PFGE plugs were cut (2.0 mm)
and digested with 40 U PmeI enzyme (New England
Biolabs, Beverly, MA, USA) for 6 hours at 37°C under
BSL-2 conditions. Salmonella enterica serotype
Braenderup (H9812) was used as a reference standard, and
DNA plugs were digested with 50 U XbaI enzyme (Roche
Diagnostics, Indianapolis, IN, USA) for 3 hours at 37°C.
Seakem agarose gels (1%) were prepared with 0.5× Tris-
borate-EDTA buffer (Sigma, Saint Louis, MO, USA), and
digested DNA plugs were loaded on the comb.
Electrophoresis was performed with a CHEF Mapper
(Bio-Rad, Hercules, CA, USA) with switch times of 1.79
to 10.71 s at 6V/cm for 17.5 h at 14°C. Gels were stained
with ethidium bromide (1 mg/mL) and gel images captured
by using a Gel Doc 1000 imager (Bio-Rad).
Analysis of PFGE gels was performed with
BioNumerics software version 3.0 (Applied Maths BVBA,
Sint-Martens-Latem, Belgium). Gels were normalized by
using the Salmonella reference strain. A dendrogram was
constructed with Dice similarity coefficients and
unweighted pair group method with averages (UPGMA).
Demographic and clinical data were analyzed with EpiInfo
2002 (CDC, Atlanta, GA, USA). To analyze categorical
data and nonparametric tests for continuous data, χ2  was
used.
Results
A total of 316 F. tularensis isolates from 39 states were
available for analysis; 208 (66%) were type A, and 108
(34%) were type B (Table 1). Among the 10 states submit-
ting at least 10 isolates, the distribution of the 2 subspecies
was nonrandom (χ2 = 34, p <0.0001). Overall, the 2 sub-
species segregated into several geographically distinct
clusters (Figure 1). Most isolates on the eastern seaboard,
in and around Arkansas and Oklahoma, and in the broad
area from the Colorado Rockies west to the Sierra Nevada
Mountains were type A. In contrast, most isolates from the
northern Pacific Coast and along tributaries of the
Mississippi River were type B.
To further understand this geographic clustering, we
developed a PFGE subtyping method for F. tularensis
using PmeI. PFGE differentiated both between type A and
B strains and among type A strains (Figure 2). Electro-
phoresis conditions were optimized to resolve restriction
fragments between 25 kb and 125 kb for both F. tularensis
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ing verified that no differences in PFGE patterns were
observed between experiments.
Comparison of PFGE patterns for a subset of isolates
(41 type A, 22 type B) from distinct locations (Figure 3)
showed that all 22 type B isolates yielded the same PFGE
pattern, which is consistent with previous data showing
that type B strains exhibit little genetic diversity (7). In
contrast, the type Aisolates yielded PFGE patterns that fell
into 2 main clusters (Figure 3; 32 type A-east, 9 type A-
west). Isolates from 1 cluster came from states completely
west of the 100th meridian (type A-west), while the
remainder came from states transecting or east of the 100th
meridian (type A-east, Figure 1). Based on the PFGE clus-
tering, subsequent epidemiologic analysis was performed
separately for type A isolates from the eastern (n = 133;
type A-east) and western (n = 71; type A-west) contiguous
United States.
Information on age and sex was known for 290 (92%)
and 312 (99%) source patients, respectively. Males
accounted for 75% (157/208) of type A and 72% (75/104)
of type B infections. Patients with type A infections were
significantly younger than patients with type B infections
(median age 38 years vs. 50 years, p<0.01), and patients
with type A-west infections were significantly younger
than those with type A-east infections (median age 33
years vs. 44 years, p <0.02). An immunocompromising
condition (e.g., malignancy, organ transplant, and HIV
infection) was reported for 11 (10%) of 108 type B–infect-
ed patients, 6 (5%) of 133 type A-east–infected patients,
and none (0%) of 68 type A-west–infected patients
(p<0.01). For the 235 (74%) source patients for whom out-
come was known, the overall case-fatality rate was 9%
(20/235), with similar rates for infections caused by type A
(9%, [15/161]) and type B (7% [5/74]) isolates. However,
among type A infections, case-fatality rates differed
markedly between type A-east (14% [15/106]) and type A-
west (0% [0/55]) (p<0.002).
Information on anatomic source was available for 280
(89%) isolates. Overall, more than half of the isolates were
recovered from lymph nodes and a quarter from blood
(Table 2). While type A and type B isolates did not differ
significantly with respect to anatomic source, significant
differences were observed between type A-west and both
type A-east (p<0.001) and type B (p<0.002) isolates. Type
A-east and type B isolates were more likely than type A-
west isolates to be recovered from blood and lung (Table
2), whereas type A-west isolates were more likely to be
recovered from lymph nodes.
The clinical form of the disease was known for only
104 (33%) source patients. Ulceroglandular and glandular
were the most commonly reported clinical forms of
tularemia, accounting for 68 (65%) of 104 cases with
information available. Other clinical syndromes included
pneumonic (17%, 18/104), typhoidal (12%, 12/104), ocu-
loglandular (4%, 4/104), meningitic (1%, 1/104) and pha-
ryngeal (1%, 1/104) forms. Patients with typhoidal or
pneumonic disease were generally older (median age 48
years and 53 years, respectively) than those with either
glandular or ulceroglandular disease (median age 11 years
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Figure 1. Geographic distribution for type A (red circles) and type
B (yellow circles) Francisella tularensis isolates from humans, con-
tiguous United States, 1964–2004. Each circle represents 1 iso-
late. Isolates were plotted randomly within the county of exposure.
The 100th meridian is indicated by the black line transecting the
United States. County of exposure was known for 198 (63%) iso-
lates.
Figure 2. PmeI pulsed-field gel electrophoresis patterns for
Francisella tularensis type A and type B. Lanes 1 and 8,
Salmonella enterica serotype Braenderup standard; lane 2,
Virginia 1997 type B; lane 3, Indiana 1999 type B; lane 4, New
York 2004 type A-east; lane 5, Oklahoma 2001 type A-east; lane
6, Oregon 2004 type A-west; lane 7, California 2002 type A-west.and 37 years, respectively). Among the subset of patients
for whom a clinical form of infection was reported, glan-
dular or ulceroglandular disease was diagnosed more fre-
quently in patients with type Ainfections (71% vs. 52% for
type B) and pneumonic disease was diagnosed less fre-
quently (12% vs. 30% for type B).
Among 292 source patients whose date of disease onset
was known, 210 (72%) were infected in May through
September; no difference in onset between type A and B
infections was noted (Figure 4). Apossible source of infec-
tions was reported for 133 (42%) of 316 patients. Direct
animal contact accounted for 47 (47%) of 99 type Aand 18
(53%) of 34 type B infections. Most type Ainfections were
associated with exposure to either lagomorphs (53%,
25/47) or cats (30%, 14/47). Type B infections were most
often associated with exposure to rodents (33%, 6/18) or
cats (22%, 4/18); none were linked to lagomorph exposure.
Arthropod bites accounted for 44 (44%) type A infections
and 10 (29%) type B infections. Although the arthropod
involved was not always identified, ticks were reported as
the source for 21 (100%) of 21 type A-east, 9 (100%) of 9
type B, and 4 (44%) of 9 type A-west infections. Biting
flies were only linked to type A-west infections and
accounted for 5 (55%) of 9 type A-west infections attrib-
uted to a known arthropod bite. The remaining 8 (8%) type
Aand 6 (18%) type B infections were in patients with both
animal and arthropod exposure or were attributed to envi-
ronmental exposures such as landscaping.
Discussion
Categorization of F. tularensis type A and type B was
first proposed by Olsufiev et al. in 1959 (16). These 2 sub-
species have been suggested to differ in their ecology and
possibly their virulence for humans (17). Our study, which
includes isolates obtained during a 40-year period, further
refines these views. By combining PFGE subtyping of iso-
lates with geographic data, we found evidence that human
type A infections can be further divided into at least 2 dis-
tinct subgroups (type A-east and type A-west). In addition,
our data suggest that type A-west infections are less severe
than type B or type A-east infections.
The most notable finding of this investigation concerns
fatality rates. The case-fatality rate for type A-east infec-
tions was 14%, compared with 7% for type B infections
and 0% for type A-west infections. Type A-east and type B
isolates were more likely to have been recovered from
patients’lungs or blood, whereas type A-west isolates were
more often isolated from lymph nodes. The apparent
reduced invasiveness of type A-west strains may be
explained by the younger age of the patients infected.
However, a review of the literature shows that few, if any,
tularemia deaths have been reported in the Rocky
Mountain region (18–21), regardless of patient age. We
hypothesize that the milder form of clinical disease associ-
ated with type A-west may be due to differences in viru-
lence factors or perhaps infectious doses associated with
differing modes of transmission.
Infections caused by type A-west, type A-east, and type
B appear to occur in distinct geographic foci, suggestive of
different ecologic niches. Type B infections cluster along
major waterways, such as the upper Mississippi River, and
in areas with high rainfall, such as coastal areas of the
Pacific Northwest. Type A-west infections predominate in
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Figure 3. Dendrogram based on PmeI pulsed-field gel elec-
trophoresis patterns of 41 Francisella tularensis type Aand 22 type
B isolates from humans. A 1.5% optimization and 1.5% tolerance
were used to calculate Dice similarity coefficients. Isolate informa-
tion is given with respect to exposure state and year.the arid region from the Rocky Mountains west to the
Sierra Nevada Mountains. Type A-east infections occur in
2 main areas: 1) the central southeast states of Arkansas,
Missouri, and Oklahoma and 2) along the Atlantic Coast,
east of the Appalachians. The central southeast region is a
major focus of human tularemia, accounting for 50% of all
reported cases in the United States (22). The type A-east
infections along the Atlantic Coast may be linked to the
importation of rabbits from Arkansas, Oklahoma,
Missouri, and Kansas to hunting clubs in Massachusetts,
Pennsylvania, New Jersey, and Maryland in the 1920s and
1930s (17,23). Whether the geographic demarcation of
type A-west and type A-east adheres strictly with the 100th
meridian will require further PFGE analysis of more type
A strains.
Animal studies have indicated that type A isolates are
often associated with lagomorphs (rabbits and hares),
while type B isolates are more often obtained from rodents
(12,17). Consistent with these findings, our results show
that human type A-east and type A-west infections were
associated with exposure to lagomorphs, whereas human
type B infections were associated with exposure to
rodents. Both type A and type B infections were associat-
ed with exposure to cats. Ticks were implicated in trans-
mission of both type A-east and type B infections to
humans, whereas biting flies were only implicated in trans-
mission of type A-west infections. The restriction of deer-
flies (Chrysops spp.) and associated human cases to
western states was previously noted by Jellison (24).
This study is subject to several limitations, including
record completeness, ascertainment bias, and number of F.
tularensis isolates PFGE subtyped. Subspecies differentia-
tion for F. tularensis has historically been dependent on the
recovery of an isolate, and subtype information is not cap-
tured in the national disease reporting system. The overall
case-fatality rate in this study was 9%, which is severalfold
higher than the <2% previously reported (25). The higher
rate suggests enhanced ascertainment of fatal cases. In
addition, 36% of type A-east and 25% of type B isolates
were recovered from blood, a much higher rate than previ-
ously reported. By analyzing only patients with culture-
confirmed infections, we may have selected for patients
with more fulminant disease.
Our results demonstrate that PmeI PFGE subtyping is
useful for dividing type A isolates into geographically and
clinically meaningful subgroups. Nineteen type A isolates
analyzed by PFGE in this study (12 type A-east, 7 type A-
west) were previously analyzed by MLVAand divided into
2 subpopulations, A.I and A.II (26). Subpopulations inde-
pendently identified by the 2 methods are in complete
agreement, which suggests that type A-west is analogous
to A.II and type A-east is analogous to A.I. With training
and interlaboratory validation, the PFGE method described
here could be adopted by PulseNet laboratories throughout
the country that use the standardized PulseNet PFGE pro-
tocol for foodborne pathogens (27). The PulseNet network
is an existing laboratory infrastructure with all of the nec-
essary equipment and software to perform, normalize, and
compare PFGE patterns. PFGE subtyping of F. tularensis
isolates would allow states to determine the potential geo-
graphic origins of tularemia cases and also share and com-
pare their PFGE patterns within the PulseNet network.
Although type A is often referred to as the more viru-
lent subspecies of F. tularensis and of greatest concern
with respect to bioterrorism, our comparative analysis sug-
gests that this view should be reevaluated. We found that
human type A-west infections are markedly less severe
than type B infections. Further studies are warranted to
determine the basis of the clinical, geographic, and ecolog-
ic differences between infections caused by type B, type A-
west, and type A-east.
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